TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arbutus Biopharma ( (ABUS) ) has issued an announcement.
On November 13, 2025, Arbutus Biopharma reported its third quarter financial results, highlighting a strong financial position with $93.7 million in cash and marketable securities. The company announced significant progress in its clinical trials for imdusiran, with 46% of Phase 2a patients meeting criteria to discontinue treatment and 94% of long-term follow-up patients remaining off treatment for over two years. Arbutus is also involved in ongoing litigation with Moderna and Pfizer/BioNTech over its LNP technology, with a favorable ruling in the Pfizer-BioNTech case and a trial against Moderna set for March 2026. Financially, the company reported a net loss of $7.7 million for the quarter, a decrease from the previous year, due to cost-cutting measures and a focus on advancing clinical development.
The most recent analyst rating on (ABUS) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Arbutus Biopharma stock, see the ABUS Stock Forecast page.
Spark’s Take on ABUS Stock
According to Spark, TipRanks’ AI Analyst, ABUS is a Neutral.
The overall stock score reflects significant financial challenges, with persistent losses and negative cash flows weighing heavily. Positive technical indicators provide some optimism, but valuation remains a concern due to negative earnings. The absence of earnings call insights or corporate events further limits the score.
To see Spark’s full report on ABUS stock, click here.
More about Arbutus Biopharma
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing treatments for infectious diseases, particularly chronic hepatitis B. The company is engaged in the development of its lead product candidate, imdusiran, and is involved in litigation to protect its intellectual property related to lipid nanoparticle (LNP) technology.
Average Trading Volume: 1,152,672
Technical Sentiment Signal: Buy
Current Market Cap: $927.8M
Learn more about ABUS stock on TipRanks’ Stock Analysis page.